842,669 Shares in Lantern Pharma Inc. $LTRN Purchased by Empery Asset Management LP

Empery Asset Management LP purchased a new stake in shares of Lantern Pharma Inc. (NASDAQ:LTRN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 842,669 shares of the company’s stock, valued at approximately $3,513,930,000. Lantern Pharma comprises about 4.1% of Empery Asset Management LP’s investment portfolio, making the stock its 7th largest holding. Empery Asset Management LP owned about 6.60% of Lantern Pharma as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LTRN. XTX Topco Ltd bought a new stake in Lantern Pharma in the second quarter worth about $40,000. Vanguard Group Inc. grew its stake in shares of Lantern Pharma by 5.6% during the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock valued at $1,671,000 after buying an additional 20,321 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Lantern Pharma during the third quarter valued at approximately $70,000. Susquehanna International Group LLP purchased a new stake in shares of Lantern Pharma in the third quarter worth approximately $170,000. Finally, Geode Capital Management LLC raised its holdings in shares of Lantern Pharma by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock worth $293,000 after buying an additional 4,661 shares during the period. 28.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LTRN has been the subject of a number of recent analyst reports. Weiss Ratings upgraded Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded Lantern Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Lantern Pharma Price Performance

NASDAQ:LTRN opened at $2.34 on Friday. Lantern Pharma Inc. has a 1-year low of $1.11 and a 1-year high of $4.70. The company has a 50-day moving average of $3.17 and a 200 day moving average of $2.83. The firm has a market cap of $29.91 million, a PE ratio of -1.44 and a beta of 2.34.

Lantern Pharma (NASDAQ:LTRN) last posted its earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.19).

Lantern Pharma Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.